Avadel Pharmaceuticals Presents LUMRYZ Findings at World Sleep Conference
At the prestigious World Sleep 2025 conference, Avadel Pharmaceuticals plc, a company focused on innovative medicine, is excited to share groundbreaking findings regarding LUMRYZ™, its once-nightly sodium oxybate treatment for narcolepsy. This year, the conference is set to showcase a wealth of research, including one oral presentation and 16 poster presentations around the efficacy of LUMRYZ.
New Insights from the REFRESH Study
Understanding the Impact of Once-Nightly Dosing
New data from the REFRESH study highlights the significant advantages of a once-nightly dosing regimen over traditional twice-nightly options. As described by Dr. Gerard J. Meskill, the CEO of Tricoastal Narcolepsy and Sleep Disorders Center, having a single bedtime dose means patients do not have the anxiety of missing a dose in the night, leading to better medication adherence and overall reduced burdens for both the patients and their partners.
Exploring Benefits for Narcolepsy Patients
Results from Clinical Highlights
Highlights from the World Sleep event illustrate that participants who switched to LUMRYZ or were new to treatment experienced clinically relevant improvements. For the 51 patients involved in the REFRESH study, key metrics indicating efficacy, like the Epworth Sleepiness Scale scores, saw significant improvements—demonstrating a move towards normal ranges of sleepiness. The study also noted a reduction of symptoms on the Narcolepsy Severity Scale and the Sheehan Disability Scale, suggesting an overall enhancement in patients' daily functioning.
Data on Comorbidities in Narcolepsy Patients
Understanding Related Health Conditions
In addition to immediate treatment outcomes, Avadel’s presentations will include intriguing analyses on the comorbidities associated with narcolepsy. A study involved 1,659 narcolepsy patients compared with matched controls, pointing out that sleep disorders, mental health issues, and chronic pain conditions occur more frequently in narcolepsy patients. Awareness of these comorbidities is critical as it helps in understanding the full impact of narcolepsy on overall health and enhances treatment planning.
Future Directions for LUMRYZ and Narcolepsy Treatment
The Road Ahead
Avadel continues to position LUMRYZ as a transformative option for patients grappling with narcolepsy, emphasizing the promising avenues identified through its real-world studies. As more data is gathered and analyzed, the hope is to firmly establish LUMRYZ as the go-to treatment option that comprehensively addresses narcolepsy symptoms and improves patients' quality of life.
About LUMRYZ™
LUMRYZ is a novel extended-release treatment approved for cataplexy and excessive daytime sleepiness in patients aged seven and older. Launching in 2023, this medication has been underpinned by successful results from pivotal trials, demonstrating significant improvements compared to placebo. The FDA granted it orphan drug exclusivity based on its unique once-nightly dosing, addressing a critical gap in narcolepsy management.
Contact Information
If you're interested in more information, please contact Avadel's investor relations at Austin Murtagh at Austin.Murtagh@precisionAQ.com or call (212) 698-8696.
Frequently Asked Questions
What is LUMRYZ used for?
LUMRYZ is used to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy aged seven years and older.
When was LUMRYZ approved?
LUMRYZ was approved by the FDA in May 2023.
What are the primary outcomes of the REFRESH study?
The REFRESH study demonstrated clinical improvements in excessive daytime sleepiness and narcolepsy symptoms in participants switching to LUMRYZ.
What were the findings regarding comorbidities in narcolepsy patients?
Higher rates of sleep, pain, and psychiatric disorders were observed in narcolepsy patients compared to controls.
Where can I find more information on LUMRYZ?
More detailed information can be found on the Avadel Pharmaceuticals website or by contacting their investor relations.
